First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
At a glance
- Drugs MSB 2311 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MabSpace Biosciences
- 13 Apr 2018 According to a MabSpace Biosciences media release, Syneos Healthcare and Q2 Solutions are supporting this trial.
- 13 Apr 2018 According to a MabSpace Biosciences media release, first patient has been dosed.
- 13 Apr 2018 Status changed from not yet recruiting to recruiting, according to a MabSpace Biosciences media release.